COVID-19 OUTPATIENT TREATMENT STUDY

A5395 A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 (Haz-COVID)

If you wish to speak with one of our staff about our study, please leave us a message, and we'll get back to you ASAP.

Si desea hablar con un miembro de nuestro personal sobre nuestro estudio, por favor déjenos un mensaje y le responderemos lo antes posible.

Effective therapies for COVID-19 are urgently needed. To help discover effective treatments in this time of crisis, we are putting our scientific and clinical expertise towards helping to determine an effective treatment for this new disease.

Hydroxychloroquine (HCQ) has shown promise in a lab setting against SARS-CoV-2, the virus that causes COVID-19; and preliminary reports suggest potential efficacy in small studies with patients.

 

However, we really, really need rigorous clinical trial data to determine whether hydroxychloroquine is effective and safe in treating COVID-19.

Main Purpose of this Investigational Study:

This study will see if low-dose hydroxychloroquine (HCQ) and azithromycin (Azithro) treatment will prevent hospitalizations and death in adults with COVID-19.

 

Main Requirements to Enter This Study:

  • 18 years of age or older

  • Positive test of the nose or throat for COVID-19 RNA from any respiratory specimen (collected within 96 hours prior to when the first dose of study treatment is expected to be taken)

  • Experiencing at least one of the following symptoms: fever, cough, or shortness of breath

  • Agreement to not participate in another COVID-19 study during the study period or take HCQ or Azithro from a source outside of the study. (If a participant is hospitalized during the study, they can participate in another COVID-19 study.)

 

Length of Study: 

24 weeks

(including 7 days of treatment, 23 weeks of follow-up)

Overview of Study:

Most participants will have visits by phone or telemedicine.

 

Participants will have a 50/50 chance (like flipping a coin) of receiving the active treatment or placebos. Neither the study staff nor the participants will know which arm they are in.

There will be 10-11 visits by phone total.

During the first few days of the study you will be taking study medication. Neither the study staff nor you will know whether you have been randomly assigned to receive study drugs of Hydroxychloroquine (HCQ) and Azithromycin (Azithro) or look-alike placebos. You will take:

 

  • HCQ (or placebo) as 2 pills twice per day for one day, then 1 pill twice per day for 6 more days (with food or glass of milk)

 

AND

 

  • Azithro (or placebo) as 2 pills on first day and 1 pill on the next 4 days

You will be contacted by the study site on a regular basis during the first three weeks and then again after 3 and 6 months.

After 3 weeks you will return your symptom/medication diary to the study site, either in person or as instructed by the study site.

 

We ask that you contact the study site if at any time during the study you get hospitalized.

 

A small number of people enrolled in the study will have blood drawn and nasal swabs performed at their study site on the first day of study, after 1 week of study and then nasal swabs obtained at the week 3 visit.

 

If you are in this group, the study staff will arrange these in-person visits with you.

Study Medication:
HCQ or Placebo 400 mg (two 200 mg capsules) by mouth twice at least 8 hours apart starting on the first day, followed by 200 mg (one capsule) twice a day for 6 days. Hydroxychloroquine/Placebo should be taken with food or milk.


PLUS

Azithro or Placebo two (250 mg each) capsules by mouth once on the first day and then one capsule (250 mg) every day for 4 additional days.
 

The medications can be taken together.

 

Study Procedures:

Visits by telephone or telemedicine, medical history, study diary (symptoms and
medicine-taking), information about any subsequent hospitalization, provide emergency contact information.

 

Reimbursement:  

$50 after the study diary has been returned on or after day 20.

 

Substudy:  

A subset of participants will be asked to have 3 of the visits in-person and have blood draws, a self-collected nose swab, and a staff-collected deep nose swab. Additional reimbursement will be provided for these procedures ($90 total).

Contact: Contact ACTU Staff at 206-773-7129 (text or call) or use the appointment button below.

Our Director Talks to UW Medicine About Our Study:

Dr. Ann Collier, Professor of Medicine, Division of Allergy and Infectious Diseases at the University of Washington School of Medicine, explains our outpatient treament study, which is looking to enroll 2,000 people newly diagnosed with Covid-19 in Washington State and across the country.

 

This research project is a separate from another hydroxychloroquine clinical study at UW Medicine, but the results will complement each other. 

Our Community Meeting on Covid-19 and HIV:

On March 24, 2020, our Associate Director, Dr. Rachel Bender Ignacio, talked to our local community advisory board, as well as other interested allies, in everything we know and don't know about Covid-19 and HIV, including all the things someone living with HIV can do to stay safe during the current pandemic. She answered the many questions that our audience asked with clarity and compassion. There's much to gain by watching this video!

DR. ANN COLLIER EXPLAINS WHY WE ARE CONDUCTING COVID-19 RESEARCH

The introduction from our April 28, 2020 Community Advisory Board meeting, where our Director, Dr. Ann Collier gives some background on COVID-19 and explains what led the AIDS Clinical Trials Group, a federally funded HIV treatment research network, to conduct COVID-19 research.

Harborview Medical Center

325 9th Avenue

2nd Floor West Clinic

Seattle, WA 98104

  • Facebook Social Icon
  • Twitter Social Icon
For Life-Threatening Emergencies Call 911

© 2023 by UW AIDS Clinical Trials Unit. Proudly created with Wix.com